Treatment for Brain Metastases

Publication Date: December 21, 2021

Key Points

Key Points

In the United States, it is estimated that between 8% and 10% of patients with cancer will develop brain metastases representing ~200,000 new patients with brain metastases every year.

The most likely primary cancers to seed brain metastases are melanoma, lung adenocarcinoma, and those from lung, breast, melanoma, renal, kidney, esophagus, and, head and neck.

This guideline was developed by a multi-disciplinary team of medical oncologists, neurosurgeons, neuro-oncologists and radiation oncologists, and it integrates the latest evidence supporting the use of surgery, radiation, and medical therapies for patients with CNS metastases.

Treatment

...atment...

...ation 1.1Surgery may be offered for p...


...ecommendation 1.2Where surgery is consid...


...commendation 1.3No recommendation can b...


...ation 2.1Patients with symptomatic brain m...


...dation 2.2For patients with asymptoma...


...endation 2.3 Osimertinib or icotinib may be offer...


Recommendation 2.4Alectinib, brigatinib, or...


...endation 2.5Pembrolizumab may be offered to patien...


...ecommendation 2.6Ipilimumab plus nivo...


....7The combination of tucatinib, trastuzumab, a...


...dation 3.1Radiation therapy should not be...


...ndation 3.2SRS alone (as opposed to WBRT...


...ommendation 3.3SRS alone should be o...


...ecommendation 3.4SRS, WBRT, and th...


...mendation 3.5Memantine and hippocampal...


...ion 3.6Radiation sensitizing agents should no...


...tion 4.1For patients who will receive bo...


...lieves that cancer clinical trials are vital to...